Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: TTI-101|DRUG: Palbociclib|DRUG: Aromatase inhibitor (AI)|DRUG: fulvestrant|DRUG: ribociclib
Sponsor: Tvardi Therapeutics, Incorporated